| Trial ID: | L1877 |
| Source ID: | NCT00875394
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00875394/results
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: sitagliptin phosphate|DRUG: Comparator: metformin|DRUG: Comparator: metformin|DRUG: Comparator: Antidiabetic Standard of Care
|
| Outcome Measures: |
Primary: Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24, Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values., Baseline and 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
68
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-02-01
|
| Completion Date: |
2008-06-27
|
| Results First Posted: |
2011-04-20
|
| Last Update Posted: |
2017-05-30
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00875394
|
